Expression of RXFP2 receptor on human spermatozoa and the anti‐apoptotic and antioxidant effects of insulin‐like factor 3. (18th June 2020)

• Record Type: Journal Article
• Authors: Shokri, Saeed; Tavalaee, Marziyeh; Ebrahimi, Seyyed Meisam; Ziaeipour, Sanaz; Nasr‐Esfahani, Mohammad Hossein; Nejatbakhsh, Reza
• Is Part Of: Andrologia. Volume 52:Number 9(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-06-18
• Subjects: apoptosis -- insulin‐like factor 3 -- RXFP2 -- spermatozoa; Andrology -- Periodicals; Infertility, Male -- Periodicals; 616.69
• DOI: 10.1111/and.13715
• Languages: English
• ISSNs: 0303-4569

Abstract

Abstract: Insulin‐like factor 3 (INSL3) has an important role in the human reproductive system; however, its detailed function is still mysterious. We aimed to investigate the possibility of expression of RXFP2 receptor on human spermatozoa and to determine the anti‐apoptotic and antioxidant mechanism derived the binding of INSL3 and RXFP2. In this experimental study, the expression/location of the RXFP2 receptor was determined on the spermatozoa of fertile and infertile men. Twenty samples from 20 fertile men were collected and divided into 6 parts (control group, and five groups treated with INSL3 10, 100, 250, 500, 1, 000 ng/ml). DNA damage, active caspase, reactive oxygen species (ROS) and sperm parameters were evaluated by TUNEL, flow cytometry, optical microscope and computer‐assisted sperm analysis. The expression of RXFP2 was confirmed by Western blot. Immunocytochemistry illustrated that this receptor is expressed in the posterior half of the spermatozoa's head. The INSL3 at concentrations of 500 and 1, 000 ng/ml reduced the active caspase and mitochondrial ROS, and also reduced DNA fragmentation at 1, 000 ng/ml. Besides, INSL3 500 and 1, 000 ng/ml significantly increased the sperm motility. This study confirmed the presence of RXFP2 receptor in fertile and infertile men's spermatozoa, indicating the highly dose‐dependent efficacy of the INSL3, which may have promising impacts on the in‐vitro fertilisation outcomes.